eutivacaftor/tezacaftor/vanzacaftor (Alyftrek)

Indications

• treatment of cystic fibrosis in adults & children >= 6 years with at least one mutation in F508del or another responsive mutation in the CFTR gene

Dosage

• once daily

Adverse effects

• boxed warning
  • risk of drug-induced liver injury & liver failure

Mechanism of action

• CFTR modulator

More general terms

• pulmonary agent
• pharmacologic combination

Components

• deutivacaftor
• tezacaftor
• vanzacaftor